Impact of Proteasome Inhibition on Anti-Donor HLA Antibody Production After Kidney Transplantation

Disorder of Transplanted Kidney Clinical Trial

Official title:
Impact of Proteasome Inhibition on Anti-Donor HLA Antibody Production After Kidney Transplantation

Status Terminated

Clinical Trial Summary

The purpose of this study is to see if treating patients who have high levels of donor specific alloantibodies post-transplant with bortezomib might prevent the development of transplant glomerulopathy and preserve allograft function.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

Disorder of Transplanted Kidney

Clinical Trial Details

NCT number	NCT01349595
Study type	Interventional
Source	Mayo Clinic
Contact
Status	Terminated
Phase	Phase 2
Start date	December 2011
Completion date	March 2015

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02017990` - Plasma Marine n-3 Polyunsaturated Fatty Acids and Patient and Graft Survival	N/A
Completed	`NCT02902120` - HCV Treatment Immune Response With Grazoprevir/Elbasvir Before or After Renal Transplant	Phase 4
Completed	`NCT01436747` - Efficacy and Safety of Paricalcitol for Reduction of Proteinuria in Kidney Transplant Recipients	Phase 3
Recruiting	`NCT01353053` - Comparison of Two Immunosuppressive Regimens in Kidney Transplant Recipients With Deceased Donors With the Aim of Preventing the Development of Fibrosis / Atrophy of Reducing the Incidence of Cytomegalovirus Infection	N/A